Coronary Heart Disease
Conditions
Keywords
CHD, DCB, SAPT, Ticagrelor
Brief summary
The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB) therapy.
Detailed description
This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center Study. There will be 234 patients with high-risk bleeding and primary coronary small vessel disease after DCB enrolled in our research, randomly dividing into an experimental group (Ticagrelor SAPT, 90mg BID \* 1 month, followed by 60mg BID, n=117) and a control group (DAPT, aspirin 100mg QD+clopidogrel 75mg QD \* 1 month, followed by clopidogrel 75mg QD, n=117).The primary endpoint is 12 months of Major adverse cardiovascular events (MACE), including death, myocardial infarction, stroke, and target vessel revascularization. The key secondary endpoint is MACE at 1 month. The safety endpoint is BARC bleeding at all levels. Follow up will be conducted at 1 month and 12 months, and platelet inhibition rate will be measured.
Interventions
DRUGTicagrelor
Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
DRUGClopidogrel
Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
DRUGAspirin
Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
Sponsors
Fu Wai Hospital, Beijing, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. CHD patients aged 18-80 with clear indications for PCI, regardless of gender; 2. Received DCB treatment with only one small coronary artery (diameter 2.0-2.75mm); 3. High risk of bleeding (ARC high risk criteria for bleeding): Meets at least one main criterion (use of anticoagulants, liver dysfunction, tumors, history of gastrointestinal bleeding, history of peptic ulcers, creatinine clearance rate\<30mL/min, hemoglobin\<11g/L, platelet count\<100 × 109/L) or 2 sub criteria (age ≥ 75 years old, creatinine clearance rate\<60mL/min, history of stroke/TIA, hemoglobin 11-12.9g/L for males or 11-11.9g/L for females); 4. Willing to participate in trials and complete follow-up; 5. Signed an informed consent form approved by the Ethics Committee;
Exclusion criteria
1. Simultaneously or plan to perform other coronary PCI procedures in batches, including stent implantation, DCB treatment for non-small vessel lesions, and DCB treatment for in stent restenosis lesions. 2. High ischemic risk: a. ACS within 1 year; b. Perform stent implantation or CABG surgery within 1 year; c. Double or multi vessel lesions rearched incomplete revascularization; d. In addition to the target lesions for DCB intervention, there are other stenosis ≥ 90%, regardless of whether PCI is planned or not; 3. Anticoagulant drugs are required for atrial fibrillation/deep vein thrombosis (including pulmonary embolism)/mechanical valve implantation; 4. Cardiomyopathy (HCM/DCM/RCM); 5. Severe ventricular arrhythmias requires radiofrequency ablation or ICD implantation; 6. Chronic obstructive pulmonary disease (bronchial asthma, chronic bronchitis, emphysema, pulmonary heart disease); 7. Serious infectious diseases, including active hepatitis B, hepatitis C or AIDS patients; 8. Blood system diseases with coagulation disorders such as thrombocytopenia, leukemia, and hemophilia; 9. Thrombotic diseases such as antiphospholipid antibody syndrome; 10. Cognitive impairment; 11. Not willing to participate in experiments or cooperate with follow-up;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiovascular Events | 12 months after randomization | A composite of mortality, non-fatal myocardial infarction, non-fatal stroke or target vessel revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiovascular Events (Key secondary endpoint) | 1 month after randomization | A composite of mortality, non-fatal myocardial infarction, non-fatal stroke or target vessel revascularization |
| Platelet inhibition rate (thromboelastogram) | 12 months after randomization | — |
| Rate of patients taking medicine as prescribed | 12 months after randomization | — |
| Rate of patients discontinued medication due to bleeding | 12 months after randomization | — |
Countries
China
Contacts
Primary ContactHaiyan Qian, MD, PhD
Backup ContactZhiyao Wei
Outcome results
None listed